A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

P-cadherin is a cell-cell adhesion molecule that is overexpressed in several solid tumors. PF-06671008 is a T-cell–redirecting bispecific antibody that engages both P-cadherin on tumors and CD3ϵ on T cells and induces antitumor activity in preclinical models. We conducted a phase 1, open-label, firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Garrido-Laguna, Ignacio, Chen, Xiaoying, Basu, Cynthia, Dowlati, Afshin, Forgie, Alison, Hooper, Andrea T., Kamperschroer, Cris, Max, Steven I., Moreau, Allison, Shannon, Megan, Wong, Gilbert Y., Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047766/
https://www.ncbi.nlm.nih.gov/pubmed/35493516
http://dx.doi.org/10.3389/fimmu.2022.845417

Ejemplares similares

Ejemplares similares